Drugs / SER-401
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03817125 | Jan 2019 → Mar 2022 | metastatic melanoma | Parker Institute for Cancer Immunotherapy | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03817125 ↗ |